» Articles » PMID: 37251345

Proarrhythmia Associated with Antiarrhythmic Drugs: a Comprehensive Disproportionality Analysis of the FDA Adverse Event Reporting System

Overview
Journal Front Pharmacol
Date 2023 May 30
PMID 37251345
Authors
Affiliations
Soon will be listed here.
Abstract

This study aimed to identify the different associations between antiarrhythmic drugs (AADs) and arrhythmias, and to determine whether pharmacokinetic drug interactions involving AADs increase the risk of AAD-related arrhythmias compared to using AADs alone. The disproportionality analysis of AAD-associated cardiac arrhythmias, including AAD monotherapies and concomitant use of pharmacokinetic interacting agents involving AADs, was conducted by using reporting odds ratio (ROR) and information component (IC) as detection of potential safety signals based on FAERS data from January 2016 to June 2022. We compared the clinical features of patients reported with AAD-associated arrhythmias between fatal and non-fatal groups, and further investigated the onset time (TTO) following different AAD regimens. A total of 11754 AAD-associated cardiac arrhythmias reports were identified, which was more likely to occur in the elderly (52.17%). Significant signals were detected between cardiac arrhythmia and all AAD monotherapies, with ROR ranging from 4.86 with mexiletine to 11.07 with flecainide. Regarding four specific arrhythmias in High Level Term (HLT) level, the AAD monotherapies with the highest ROR were flecainide in cardiac conduction disorders (ROR025 = 21.18), propafenone in rate and rhythm disorders (ROR025 = 10.36), dofetilide in supraventricular arrhythmias (ROR025 = 17.61), and ibutilide in ventricular arrhythmias (ROR025 = 4.91). Dofetilide/ibutilide, ibutilide, mexiletine/ibutilide and dronedarone presented no signal in the above four specific arrhythmias respectively. Compared with amiodarone monotherapy, sofosbuvir plus amiodarone detected the most significantly increased ROR in arrhythmias. The investigation showed the spectrum and risk of AAD-associated cardiac arrhythmias varied among different AAD therapies. The early identification and management of AAD-associated arrhythmias are of great importance in clinical practice.

Citing Articles

A study on the pharmacovigilance of various SGLT-2 inhibitors.

Dong Y, Wang Y, Lan X, Zeng H Front Med (Lausanne). 2025; 11:1515847.

PMID: 39882521 PMC: 11774954. DOI: 10.3389/fmed.2024.1515847.


Effects of SZV-2649, a new multiple ion channel inhibitor mexiletine analogue.

Mohammed A, Naveed M, Szabados T, Szatmari I, Lorinczi B, Matyus P Sci Rep. 2024; 14(1):23188.

PMID: 39369049 PMC: 11455950. DOI: 10.1038/s41598-024-73576-5.


Prehospital point-of-care medication burden as a predictor of poor related outcomes in unselected acute diseases.

Jurado-Palomo J, Sanz-Garcia A, Martin-Conty J, Polonio-Lopez B, Lopez-Izquierdo R, Saez-Belloso S Intern Emerg Med. 2024; .

PMID: 39090370 DOI: 10.1007/s11739-024-03729-x.


Assessing the safety of bedaquiline: insight from adverse event reporting system analysis.

Wu J, Pan H, Shen L, Zhao M Front Pharmacol. 2024; 15:1382441.

PMID: 38783951 PMC: 11111899. DOI: 10.3389/fphar.2024.1382441.


SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024.

Alghamdi A, Alghamdi H, Alserehi H, Babatin M, Alswat K, Alghamdi M Saudi J Gastroenterol. 2024; 30(Supp 1):S1-S42.

PMID: 38167232 PMC: 10856511. DOI: 10.4103/sjg.sjg_333_23.


References
1.
Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C . Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019; 9:CD005049. PMC: 6738133. DOI: 10.1002/14651858.CD005049.pub5. View

2.
January C, Samuel Wann L, Calkins H, Chen L, Cigarroa J, Cleveland Jr J . 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the.... J Am Coll Cardiol. 2019; 74(1):104-132. DOI: 10.1016/j.jacc.2019.01.011. View

3.
Andrade J, Turgeon R, Macle L, Deyell M . Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. Eur Cardiol. 2022; 17:e10. PMC: 9006125. DOI: 10.15420/ecr.2021.38. View

4.
Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M . Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace. 2011; 13(3):329-45. DOI: 10.1093/europace/euq450. View

5.
Fox K, Ford I, Steg P, Tardif J, Tendera M, Ferrari R . Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014; 371(12):1091-9. DOI: 10.1056/NEJMoa1406430. View